Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripretinib versus sunitinib in advanced GIST with KIT exon 11 and 17/18 mutations after imatinib
NL-OMON59146Phase 3Active, not recruiting
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Nov 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastrointestinal stromal tumor (GIST) comparing Ripretinib with Sunitinib (2 arms). Primary endpoint: Progression-free survival by independent radiologic review. Started Nov 2023; status: active, not recruiting.
02
Drugs
ripretinibsunitinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON59146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59146.